Latest UCB News & Updates

See the latest news and media coverage for UCB. We track all announcements, press releases, and industry mentions in real time, all in one place.

UCB

Global biopharmaceutical company for neurological and immune-mediated diseases

ucb.com

Headquarters: Brussels, Belgium
Founded year: 1928
Company type: Private company
Number of employees: 10,000–16,000
Industry: Pharmaceuticals

Last updated October 22

Latest news about UCB

In short: UCB raised its 2026 financial outlook after strong demand for BIMZELX and CIMZIA.

Company announcements

October 22 UCB

UCB upgrades 2026 financial guidance on strong BIMZELX and CIMZIA performance

Higher revenue and EBITDA growth reflect robust demand for key drugs. The company excludes PRV sale proceeds from these revised expectations.

October 16 UCB

UCB announces FDA approval for ZILBRYSQ autoinjector

The self-administered device simplifies treatment for generalized myasthenia gravis patients, with commercial availability expected in Q1 2027.

September 9 UCB

UCB receives FDA breakthrough therapy designation for CIMZIA treatment

The regulatory status supports the drug to prevent adverse pregnancy outcomes in pregnant women with antiphospholipid syndrome. The designation follows positive findings from the IMPACT clinical study.

August 31 UCB

UCB reaches US government deal to lower medicine costs

The company will expand American manufacturing in Georgia, create 330 jobs, avoid pharmaceutical tariffs, and donate essential medications to the national stockpile.

Media coverage

October 22 Pulse 2.0

UCB Raises 2026 Revenue Growth Guidance To Low 20% Range And Adjusted EBITDA Growth Outlook To Low-To-Mid 40% Range

UCB, a Belgium-based global biopharmaceutical company, has raised its full-year 2026 financial guidance following stronger-than-expected commercial performance from BIMZELX and CIMZIA. The company now expects...

October 21 The Wall Street Journal

UCB Shares Jump After Demand for Immunology Drug Bimzelx Boosts Outlook

Shares were up 13%—erasing losses in the year to date—after the company raised its annual guidance for the second time this ...

October 15 Ad Hoc News

UCB upgrades 2026 guidance: UCB stock gains 14.23 percent

UCB upgrades 2026 revenue growth guidance to the low twenties. UCB stock costs EUR 243.30 on October 22, 2026 versus EUR 213.00 at the Xetra...

October 9 L'Echo

UCB regains the favor of the Brussels Stock Exchange, Bimzelx continues to surprise

The strength of Bimzelx pushes UCB to significantly raise its annual outlook. Enough to bring investors back to a stock that has been battered since July.

Never miss news about UCB

Track UCB and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

UCB competitors & trending companies

Browse news for competitors to UCB and other trending companies.